Loading...
XKRX
196170
Market cap12bUSD
Mar 31, Last price  
356,000.00KRW
1D
0.99%
1Q
15.02%
Jan 2017
987.02%
IPO
1,468.28%
Name

Alteogen Inc

Chart & Performance

D1W1MN
P/E
—
P/S
190.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.58%
Rev. gr., 5y
47.76%
Revenues
96.52b
+235.08%
3,959,773,5505,527,341,1107,042,577,9104,726,609,2496,843,719,83512,104,355,84313,703,078,87329,229,181,88342,425,842,45738,745,944,02728,806,344,49896,522,928,880
Net income
-3.37b
L-58.61%
1,433,818,3601,606,019,750931,144,4901,208,362,969-3,587,198,673-7,448,958,134-6,872,254,503-704,513,309-15,821,779,561-6,274,918,065-8,146,003,033-3,371,764,005
CFO
-7.77b
L-56.56%
1,230,719,1301,995,140,1701,210,050,1002,264,057,823-3,158,649,751-4,346,924,220-9,112,552,1269,133,183,9871,512,244,562-9,460,530,126-17,874,625,308-7,765,575,368
Earnings
May 14, 2025

Profile

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
URL
http://www.alteogen.com/
IPO date
Dec 12, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
96,522,929
235.08%
28,806,344
-25.65%
Cost of revenue
95,650,777
51,411,579
Unusual Expense (Income)
NOPBT
872,152
(22,605,234)
NOPBT Margin
0.90%
Operating Taxes
17,834
108,049
Tax Rate
2.04%
NOPAT
854,318
(22,713,283)
Net income
(3,371,764)
-58.61%
(8,146,003)
29.82%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,391,270
2,139,826
BB yield
-0.05%
-0.11%
Debt
Debt current
292,417
84,725,187
Long-term debt
1,868,297
777,757
Deferred revenue
4,701,044
4,000,000
Other long-term liabilities
1,729,324
1,021,852
Net debt
(109,600,675)
(62,324,782)
Cash flow
Cash from operating activities
(7,765,575)
(17,874,625)
CAPEX
(43,455,494)
(42,547,966)
Cash from investing activities
(9,343,034)
50,612,431
Cash from financing activities
1,736,653
2,519,640
FCF
16,781,977
(28,329,702)
Balance
Cash
110,607,100
127,539,357
Long term investments
1,154,288
20,288,369
Excess cash
106,935,242
146,387,409
Stockholders' equity
45,864,943
44,498,110
Invested Capital
110,112,145
191,295,502
ROIC
0.57%
ROCE
0.56%
EV
Common stock shares outstanding
51,660
51,282
Price
98,500.00
157.52%
38,250.00
-49.47%
Market cap
5,088,497,294
159.41%
1,961,547,286
-57.34%
EV
4,978,624,091
1,896,293,994
EBITDA
4,205,682
(19,950,924)
EV/EBITDA
1,183.79
Interest
670,884
425,481
Interest/NOPBT
76.92%